Technology innovation for infectious diseases in the developing world

Infectious Diseases of Poverty

Volumn 1, Issue 1, 2012, Pages 1-9

  So, Anthony D ^a   Ruiz Esparza, Quentin ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Access; Business model; Innovation; Open innovation; Open source; Policy; Public health; R D; R D collaboration; Technology

Indexed keywords

ARTEMISININ; CHLOROQUINE; INFLUENZA VACCINE; ORAL REHYDRATION SOLUTION; PYRIMETHAMINE PLUS SULFADOXINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DEVELOPING COUNTRY; DRUG INDUSTRY; ENDEMIC DISEASE; HUMAN; INFECTION; INFLUENZA; LOWEST INCOME GROUP; MALARIA; MEDICAL TECHNOLOGY; NEGLECTED DISEASE; PRIORITY JOURNAL; PUBLIC HEALTH; TUBERCULOSIS;

EID: 84898906524     PISSN: None     EISSN: 20499957     Source Type: Journal    
DOI: 10.1186/2049-9957-1-2     Document Type: Article

References (58)

1. Lopez AD, Mathers CD, Ezzati M, et al. Measuring the Global Burden ofDisease and Risk Factors, 1990-2001. Global Burden of Disease and Risk Factors. Chapters 1 and 2 2006, Washington, DC: The International Bank for Reconstruction and Development / The World Bank, http://www.dcp2.org/pubs/GBD/.
2. World Health Organization Mortality and Burden of Disease Estimates for WHO Member States in 2004 2009, World Health Organization.
3. United Nations Millennium Development Goals Report 2011 2011, United Nations: New York, http://www.un.org/millenniumgoals/11_MDG%20Report_EN.pdf, United Nations.
4. MDG Targets and Indicators http://www.un-ngls.org/spip.php?page=amdg10&id_article=2330.
5. Global Health Technologies Coalition / Policy Cures Saving Lives and Creating Impact: Why Investing in Global Health Research Works 2012, http://policycures.org/downloads/Saving%20lives%20and%20creating%20impact.pdf, Global Health Technologies Coalition / Policy Cures.
6. World Bank Health Expenditure per Capita, data from 1995 to 2010 2010, http://data.worldbank.org/indicator/SH.XPD.PCAP, World Bank.
7. Médecins Sans Frontières Untangling the Web of Antiretroviral Price Reductions 2011, Geneva, Switzerland: Médecins Sans Frontières, 14, Médecins Sans Frontières.
8. World Health Organization, UNICEF, UNAIDS Global HIV/AIDS Response 2011, Geneva, Switzerland: Epidemic Update and Health Sector Progress towards Universal Access World Health Organization Department of HIV/AIDS, http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_UA_Report_en.pdf, World Health Organization, UNICEF, UNAIDS.
9. UNAIDS AIDSInfo Database: Number of People Living with HIV, 1990 to 2009 2009, http://www.unaids.org/en/dataanalysis/datatools/aidsinfo/, UNAIDS.
10. World Bank Health Expenditure per Captia, data from 1995 to 2010 2010, http://data.worldbank.org/indicator/SH.XPD.PCAP, World Bank.
11. Lu Y, Hernandez P, Abegunde D, Edejer T. The World Medicines Situation 2011: Medicine Expenditures 2011, 7. Geneva, Switzerland: World Health Organization, 3.
12. Adeyi O. Affordable Medicines Facility-malaria (AMFm): Achievements to date, UNITAID Consultative Forum 2011, Geneva, Switzerland: UNITAID.
13. Health Action International Retail prices of ACTs co-paid by the AMFm and other antimalarial medicines: report of price-tracking survey 2011, Geneva, Switzerland: The Global Fund to Fight AIDS, Tuberculosis and Malaria, Health Action International.
14. Expert Advisory Group on the Affordable Medicines Facility-malaria (AMFm) Review of the AMFm Phase 1 Independent Evaluation Preliminary Report 2012, Geneva, Switzerland: The Global Fund to Fight AIDS, Tuberculosis and Malaria, Expert Advisory Group on the Affordable Medicines Facility-malaria (AMFm).
15. Rutta E, Kibassa B, McKinnon B, Liana J, Mbwasi R, Mlaki W, Embrey M, Garba M, Shekalaghe E, Kimatta S, Hiiti S. Increasing Access to Subsidized Artemisinin-based Combination Therapy through Accredited Drug Dispensing Outlets in Tanzania. Health Res Pol Syst 2011, 9:22.
16. The William Davidson Institute: Affordable Medicines Facility-malaria (AMFm) Assessment of the effects of the AMFm on market dynamics of API and ACTs at the global level 2012, Ann Arbor, Michigan: William Davidson Institute, The University of Michigan, http://www.theglobalfund.org/en/amfm/discussionpapers/, The William Davidson Institute: Affordable Medicines Facility-malaria (AMFm).
17. Zhang J, Pritchard E, Hu X, Valentin T, Panilaitis B, Omenetto FG, Kaplan DL. Stabilization of vaccines and antibiotics in silk and eliminating the cold chain. Proc Natl Acad Sci 2012, 109(30):11981-11986. 10.1073/pnas.1206210109, 22778443.
18. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, Schulman KA. Ethical and Scientific Implications of the Globalization of Clinical Research. N Engl J Med 2009, 360(8):816-823. 10.1056/NEJMsb0803929, 19228627.
19. World Health Organization Mortality and Burden of Disease Estimates for WHO Member States in 2004 2009, World Health Organization.
20. World Health Organization Mortality and Burden of Disease Estimates for WHO Member States in 2004 2009, World Health Organization.
21. Policy C. Global Funding for Innovation for Neglected Diseases (G-FINDER) 2011, http://g-finder.policycures.org/gfinder_report/.
22. Sumner A. The New Bottom Billion: What If Most of the World's Poor Live in Middle-Income Countries? 2011, Washington, DC: Center for Global Development, http://www.cgdev.org/files/1424922_file_Sumner_brief_MIC_poor_FINAL.pdf.
23. Nwaka S, Ilunga TB, Da Silva JS, Rial Verde E, Hackley D, De Vré R, Mboya-Okeyo T, Ridley RG. Developing ANDI: A Novel Approach to Health Product R&D in Africa. PLoS Med 2010, 7(6):e1000293. http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000293#pmed-1000293-g001, 10.1371/journal.pmed.1000293, 2893959, 20613865.
24. Moran M. A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need. PLoS Med 2005, 2(9):e302. http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0020302, 10.1371/journal.pmed.0020302, 1198042, 16138789.
25. Ponder E, Moree M. Developing New Drugs & Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape 2012, Washington, DC: BIO Ventures for Global Health.
26. Associated Press Innovative drug approvals up sharply in 2011, gov't increasingly funds infectious disease R&D 2012, Washington, DC: Washington Post, Associated Press.
27. Global Health Strategies Initiatives Shifting Paradigm: How the BRICS are Reshaping Global Health and Development 2012, New York, NY: Global Health Strategies Initiatives, Global Health Strategies Initiatives.
28. Institute for Applied Economic Research Brazilian Cooperation for International Development: 2005-2009 2011, Rio de Janeiro, Brazil: Institute for Applied Economic Research, Institute for Applied Economic Research.
29. GAVI Alliance Brazil: Donor Profiles, http://www.gavialliance.org/funding/donor-profiles/brazil/.
30. UNITAID UNITAID Annual Report 2011: Five Years for Better Health 2011, Geneva, Switzerland: UNITAID, UNITAID.
31. Technology transfer and establishment of an antiretroviral drugs factory in Mozambique http://www.fiotec.fiocruz.br/institucional/index.php?option=com_content&view=article&id=805:technology-transfer-and-establishment-of-an-antiretroviral-drugs-factory-in-mozambique&catid=126&Itemid=489&lang=en.
32. AFP Mozambique launches Brazil-funded drugs plant to battle HIV. Yahoo! News 2012, http://news.yahoo.com/mozambique-launches-brazil-funded-drugs-plant-battle-hiv-174318951.html, AFP.
33. Drugs for Neglected Diseases Initiative A Worldwide Public Partnership Makes Available a New, Once-a-Day Fixed-Dose Combination against Malaria 2008, Geneva, Switzlerand: Drugs for Neglected Diseases Initiative, http://dndi.org/press-releases/2008/113-a-worldwide-public-partnership-makes-available-a-new-once-a-day-fixed-dose-combination-against-malaria.html, Drugs for Neglected Diseases Initiative.
34. Lu Y, Hernandez P, Abegunde D, Edejer T. The World Medicines Situation 2011: Medicine Expenditures 2011, Geneva, Switzerland: World Health Organization, 3.
35. Commission on Intellectual Property Rights Innovation and Public Health: Public Health, Innovation and Intellectual Property Rights 2006, Geneva, Switzerland: World Health Organization, http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf, Commission on Intellectual Property Rights.
36. Sixty-First World Health Assembly Global strategy and plan of action on public health, innovation and intellectual property," WHA61.21, Agenda item 11.6 2008, http://apps.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf, Sixty-First World Health Assembly.
37. Consultative Expert Working Group on Research and Development Financing and Coordination: Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination 2012, Geneva, Switzerland: World Health Organization, http://www.who.int/phi/CEWG_Report_5_April_2012.pdf, Consultative Expert Working Group on Research and Development.
38. WHO Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits 2011, Geneva, Switzerland: World Health Organization, Available at: http://whqlibdoc.who.int/publications/2011/9789241503082_eng.pdf, WHO.
39. Hendriks J, Holleman M, de Boer O, de Jong P, Luytjes W. An international technology platform for influenza vaccines. Vaccine 2011, 29(Supplement 1):A8-A11. Available at: http://www.sciencedirect.com/science/article/pii/S0264410X11006906.
40. So AD, Stewart E. Sharing Knowledge for Global Health. The U.S. Commitment to Global Health: Recommendations for the Public and Private Sectors 2008, Washington, DC: Appendix F. U.S. Institute of Medicine Committee on the U.S. Commitment to Global Health, [http://www.ncbi.nlm.nih.gov/books/NBK23792/].
41. ChEMBL-Neglected Tropical Disease archive ChEMBL-Neglected Tropical Disease archive [https://www.ebi.ac.uk/chemblntd/], ChEMBL-Neglected Tropical Disease archive.
42. Medicines Patent Pool FAQ on the Pool/Gilead Licenses: October 2011--Frequently Asked Questions on the Implications of the Gilead/Medicines Patent Pool License [http://www.medicinespatentpool.org/licensing/current-licences/the-medicines-patent-poolgilead-licences-questions-and-answers/faq-on-the-poolgilead-licences/], Medicines Patent Pool.
43. Collins F. Reengineering translational science: the time is right. Sci Transl Med 2011, 3(90:90cm17):1-6. [http://www.nih.gov/about/director/articles/translational_science_07062011.pdf].
44. Mimura C, Cheng J, Penhoet B. Perspective: Socially Responsible Licensing, Euclidean Innovation, and the Valley of Death 2011, Stanford Journal of Law, Science and Policy, UC Berkeley Public Law Research Paper No. 1928837. [http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1928837].
45. Marshall E. Bermuda Rules: community spirit, with teeth. Science 2001, 291:1192. 10.1126/science.291.5507.1192, 11233433.
46. U.S. National Institutes of Health Final NIH Statement on Sharing Research Data, 2003 2003, Bethesda, MD: Notice NOT-OD-03-032. U.S. National Institutes of Health, [http://grants.nih.gov/grants/guide/notice-files/not-od-03-032.html], U.S. National Institutes of Health.
47. U.S. National Institutes of Health Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice 1999, Federal Register Notice, [http://www.ott.nih.gov/policy/rt_guide_final.html], U.S. National Institutes of Health.
48. Chesbrough HW. The Era of Open Innovation 2011, 35-41. Top 10 Lessons on the New Business of Innovation. MIT Sloan Management Review, (originally published Spring 2003). [http://scholar.google.com/scholar_url?hl=en&q=http://sloanreview.mit.edu/files/2011/06/INS0111-Top-Ten-Innovation.pdf%23page%3D37&sa=X&scisig=AAGBfm1PbObbGnXtYKHIQDvZFi1_CRc2Dg&oi=scholarr].
49. Council for Scientific and Industrial Research Frequently Asked Questions, Open Source Drug Discovery Initiative [http://www.osdd.net/faq-s], Council for Scientific and Industrial Research.
50. Jadhav SS, Gautam M, Gairola S. Emerging markets & emerging needs: Developing countries vaccine manufacturers' perspective & its current status. Biologicals 2009, 37:165-168. 10.1016/j.biologicals.2009.02.009, 19328010.
51. Waning B, Diedrichsen E, Moon S. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. J Int AIDS Soc 2010, 13:35. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944814/], 10.1186/1758-2652-13-35, 2944814, 20840741.
52. Radjou N, Prabhu J, Ahuja S. Jugaad Innovation: Think Frugal, Be Flexible, Generate Breakthrough Growth 2012, San Francisco, CA: Jossey-Bass.
53. Bound K, Thornton I. Our Frugal Future: Lessons from India's Innovation System 2012, London, United Kingdom: Nesta, [http://www.nesta.org.uk/library/documents/OurFrugFuture.pdf].
54. So AD, Ruiz-Esparza Q, Gupta N, Cars O. 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. Br Med J 2012, 344:e1782.
55. INSEAD, World Intellectual Property Organization The Global Innovation Index 2012: Stronger Innovation Linkages for Global Growth 2012, Fontainebleau, France: INSEAD and World Intellectual Property Organization, Edited by Dutta S, INSEAD, World Intellectual Property Organization.
56. Malhotra A, Kleiner A, Geller LW. A Gandhian Approach to R&D 2010, Strategy + Business, [http://www.strategy-business.com/article/10310?pg=all].
57. Prahalad C, Mashelkar R. Innovation's Holy Grail. Harvard Business Review 2010, 88(7/8):132-141. [serial online].
58. Clayton Christensen Key concepts--disruptive innovation [http://www.claytonchristensen.com/key-concepts/], Clayton Christensen.